Philippe Menasche

Summary

Country: France

Publications

  1. ncbi Overcoming bacterial DNA contamination in real-time PCR and RT-PCR reactions for LacZ detection in cell therapy monitoring
    Sylvie Tondeur
    Inserm E0-03, , AP-HP, , 1 avenue Claude Vellefaux, 75010 Paris, France
    Mol Cell Probes 18:437-41. 2004
  2. ncbi Cellular therapy in thoracic and cardiovascular disease
    Philippe Menasche
    Assistance Publique-Hopitaux de Paris, , Department of Cardiovascular Surgery, Paris, France
    Ann Thorac Surg 84:339-42. 2007
  3. ncbi Skeletal myoblasts as a therapeutic agent
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, University Paris Descartes, Faculte de Medecine, INSERM U 633, Paris, F 75015, France
    Prog Cardiovasc Dis 50:7-17. 2007
  4. ncbi Skeletal myoblasts and cardiac repair
    Philippe Menasche
    Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, University Paris 5, Faculte de Medecine, INSERM U 633, Laboratory of Biosurgical Research, Paris, France
    J Mol Cell Cardiol 45:545-53. 2008
  5. ncbi The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation
    Philippe Menasche
    Département de Chirurgie Cardio vasculaire, Hopital Europeen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France
    Circulation 117:1189-200. 2008
  6. ncbi Embryonic stem cells for severe heart failure: why and how?
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Unité de chirurgie de l insuffisance cardiaque, 20 rue Leblanc, Paris, France
    J Cardiovasc Transl Res 5:555-65. 2012
  7. ncbi Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, University Paris Descartes, Faculte de Medecine, INSERM U 633, Paris, France
    J Cardiovasc Transl Res 1:201-6. 2008
  8. ncbi Cardiac cell therapy: lessons from clinical trials
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Universite Paris Descartes, INSERM U 633, Paris, France
    J Mol Cell Cardiol 50:258-65. 2011
  9. ncbi Current status and future prospects for cell transplantation to prevent congestive heart failure
    Philippe Menasche
    Department of Cardiovascular Surgery, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France
    Semin Thorac Cardiovasc Surg 20:131-7. 2008
  10. ncbi Stem cell therapy for chronic heart failure: lessons from a 15-year experience
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Universite Paris Descartes, Paris, France
    C R Biol 334:489-96. 2011

Collaborators

Detail Information

Publications68

  1. ncbi Overcoming bacterial DNA contamination in real-time PCR and RT-PCR reactions for LacZ detection in cell therapy monitoring
    Sylvie Tondeur
    Inserm E0-03, , AP-HP, , 1 avenue Claude Vellefaux, 75010 Paris, France
    Mol Cell Probes 18:437-41. 2004
    ....
  2. ncbi Cellular therapy in thoracic and cardiovascular disease
    Philippe Menasche
    Assistance Publique-Hopitaux de Paris, , Department of Cardiovascular Surgery, Paris, France
    Ann Thorac Surg 84:339-42. 2007
  3. ncbi Skeletal myoblasts as a therapeutic agent
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, University Paris Descartes, Faculte de Medecine, INSERM U 633, Paris, F 75015, France
    Prog Cardiovasc Dis 50:7-17. 2007
    ..In the setting of this second generation of cells, human cardiac-specified embryonic stem cells may hold the greatest promise...
  4. ncbi Skeletal myoblasts and cardiac repair
    Philippe Menasche
    Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, University Paris 5, Faculte de Medecine, INSERM U 633, Laboratory of Biosurgical Research, Paris, France
    J Mol Cell Cardiol 45:545-53. 2008
    ....
  5. ncbi The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation
    Philippe Menasche
    Département de Chirurgie Cardio vasculaire, Hopital Europeen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France
    Circulation 117:1189-200. 2008
    ..Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they have failed to determine whether this procedure was functionally effective and arrhythmogenic...
  6. ncbi Embryonic stem cells for severe heart failure: why and how?
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Unité de chirurgie de l insuffisance cardiaque, 20 rue Leblanc, Paris, France
    J Cardiovasc Transl Res 5:555-65. 2012
    ....
  7. ncbi Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, University Paris Descartes, Faculte de Medecine, INSERM U 633, Paris, France
    J Cardiovasc Transl Res 1:201-6. 2008
    ....
  8. ncbi Cardiac cell therapy: lessons from clinical trials
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Universite Paris Descartes, INSERM U 633, Paris, France
    J Mol Cell Cardiol 50:258-65. 2011
    ..This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited"...
  9. ncbi Current status and future prospects for cell transplantation to prevent congestive heart failure
    Philippe Menasche
    Department of Cardiovascular Surgery, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France
    Semin Thorac Cardiovasc Surg 20:131-7. 2008
    ..Altogether, these observations provide a framework for future research, the results of which will then have to be integrated in the protocol design of second-generation clinical trials...
  10. ncbi Stem cell therapy for chronic heart failure: lessons from a 15-year experience
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Universite Paris Descartes, Paris, France
    C R Biol 334:489-96. 2011
    ....
  11. ncbi Challenging the cardiac differentiation of bone marrow cells: a clinical perspective
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, Paris, France
    Mol Ther 16:1000-1. 2008
  12. ncbi Stem cell therapy for heart failure: are arrhythmias a real safety concern?
    Philippe Menasche
    Department of Cardiovascular Surgery, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
    Circulation 119:2735-40. 2009
    ..The risk-to-benefit ratio of stem cell therapy will finally have to be revisited in light of the fact that because this baseline risk is usually high, most of these patients will in any way be fitted with an implantable defibrillator...
  13. ncbi Cell-based therapy for heart disease: a clinically oriented perspective
    Philippe Menasche
    Department of Cardiovascular Surgery, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France
    Mol Ther 17:758-66. 2009
    ..e., the regulator, and are thus unbypassable prerequisites for an effective and streamlined leap from bench to bedside...
  14. ncbi Cell therapy for peripheral arterial disease
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Universite Paris Descartes, INSERM U 633, Paris, France
    Curr Opin Mol Ther 12:538-45. 2010
    ....
  15. ncbi Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients
    Albert A Hagege
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    Circulation 114:I108-13. 2006
    ..Short-term follow-up (FU) studies have suggested that a similar benefit could clinically occur despite an increased risk of LV arrhythmias...
  16. ncbi Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections
    Hadhami Hamdi
    INSERM U633, Laboratory of Biosurgical Research, Paris, France
    Cardiovasc Res 91:483-91. 2011
    ..Intramyocardial injections of cells can damage tissue and enhance dissociation-induced cell death. We assessed whether epicardial delivery of cell sheets could overcome these issues in a rat model of chronic myocardial infarction...
  17. ncbi Relief of mitral leaflet tethering following chronic myocardial infarction by chordal cutting diminishes left ventricular remodeling
    Emmanuel Messas
    Hopital Europeen Georges Pompidou, Department of Cardiology, University Paris Descartes, Paris
    Circ Cardiovasc Imaging 3:679-86. 2010
    ..The purpose of this study was to test whether this technique reduces the progression of LV remodeling in the chronic ischemic MR setting...
  18. ncbi Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction
    Said Ghostine
    Inserm EMI 0016, Necker Paris V University and Department of Cardiology 1, Hopital Europeen Georges Pompidou, France
    Circulation 106:I131-6. 2002
    ..Transplantation (Tx) of skeletal myoblasts (SM) within an infarcted myocardium improves global left ventricular (LV) function, although a direct systolic effect remains controversial...
  19. ncbi Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium?
    Agnes Maurel
    1 INSERM U633, Laboratoire d Etude des Greffes et Prothèses Cardiaques, Hopital Broussais, Paris, France
    Transplantation 80:660-5. 2005
    ....
  20. ncbi Autologous myoblast transplantation for chronic ischemic mitral regurgitation
    Emmanuel Messas
    Universite Rene Descartes Paris 5, Faculté de médecine René Descartes Paris 5, Paris, France
    J Am Coll Cardiol 47:2086-93. 2006
    ..This study was designed to assess whether post-myocardial infarction (MI) in-scar transplantation of skeletal myoblasts (SM) could reduce chronic ischemic mitral regurgitation (MR) by decreasing left ventricular (LV) remodeling...
  21. ncbi Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium
    Onnik Agbulut
    INSERM U572, Hopital Lariboisiere, Paris, France
    J Am Coll Cardiol 44:458-63. 2004
    ..The present study was designed as a face-to-face functional comparison of human skeletal myoblasts (SMs) and CD133(+) bone marrow-derived hematopoietic progenitors in an animal model of semichronic myocardial infarction...
  22. ncbi Comprehensive annular and subvalvular repair of chronic ischemic mitral regurgitation improves long-term results with the least ventricular remodeling
    Catherine Szymanski
    Department of Cardio Vascular Medicine, Hopital Europeen Georges Pompidou, INSERM U 633, PARCC, 20 rue Leblanc, 75015 Paris, France
    Circulation 126:2720-7. 2012
    ..We tested whether subvalvular repair by severing second-order mitral chordae can improve annuloplasty by reducing papillary muscle tethering...
  23. ncbi Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells
    Damelys Calderon
    Inserm UMR 633, Laboratory of Surgical Research, Hoôpital Européen Georges Pompidou, Paris, France
    J Cell Mol Med 16:1544-52. 2012
    ..We propose that, in combination, these factors may limit the in vivo immunogenicity of cardiac progenitors co-implanted with ADSC in patients with CAD...
  24. ncbi Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Department of Cardiovascular Surgery B, Hopital Bichat, Paris, France
    J Am Coll Cardiol 41:1078-83. 2003
    ..This phase I trial was designed to assess the feasibility and safety of autologous skeletal myoblast transplantation in patients with severe ischemic cardiomyopathy...
  25. ncbi Self-assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium
    Gilbert Dubois
    Assistance Publique Hopitaux de Paris, Ecole de Chirurgie, Paris 75005, France
    J Biomed Mater Res B Appl Biomater 87:222-8. 2008
    ..These data suggest that the optimal use of biomaterial scaffolds for survival of transplanted cells will require specific tailoring of the biomaterial to the cell type...
  26. ncbi Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison
    Hadhami Hamdi
    INSERM U 633, Laboratory of Surgical Research, Paris, France
    Ann Thorac Surg 87:1196-203. 2009
    ..This study used skeletal myoblasts to perform a head-to-head comparison of conventional injections with epicardial deposition of scaffold-embedded cells...
  27. ncbi Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells
    Alain Bel
    Assistance Publique Hopitaux de Paris, Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, University Paris Descartes, INSERM U633, Paris, France
    Circulation 122:S118-23. 2010
    ..The safety and efficacy of myocardial regeneration using embryonic stem cells are limited by the risk of teratoma and the high rate of cell death...
  28. ncbi Prevention of postcardiopulmonary bypass pericardial adhesions by a new resorbable collagen membrane
    Alain Bel
    Department of Cardiovascular Surgery, Assistance Publique Hopitaux de Paris, Hospital European Georges Pompidou, Paris, France
    Interact Cardiovasc Thorac Surg 14:469-73. 2012
    ..This collagen membrane might thus represent an attractive pericardial substitute for preventing post-operative adhesions...
  29. ncbi [Embryonic stem cells in the treatment of severe cardiac insufficiency]
    Philippe Menasche
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Unité de chirurgie de l insuffisance cardiaque, 20 rue Leblanc, 75015 Paris, France
    Biol Aujourdhui 206:31-44. 2012
    ....
  30. ncbi Chordal cutting does not adversely affect left ventricle contractile function
    Emmanuel Messas
    Université René Descartes Paris, Faculte de Medecine, INSERM U633, Assistance Publique Hopitaux de Paris, Department of Cardiology, Hopital Europeen Georges Pompidou, Paris, France
    Circulation 114:I524-8. 2006
    ..We evaluated changes in cardiac function in 5 normal sheep with cutting of pre-instrumented chords in the beating heart to maintain constant load...
  31. ncbi Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?
    Sylvain Chanséaume
    INSERM U 633, Laboratoire d Etude des Greffes et Prothèses Cardiaques, Hôpital Broussais Assistance Publique Hôpitaux de Paris, Ecole de Chirurgie, Paris, France
    Interact Cardiovasc Thorac Surg 6:293-7. 2007
    ..In this model, EPO failed to improve myoblast engraftment and postinfarction LV function. These negative findings justify to pursue the search for alternate cell survival-enhancing strategies...
  32. ncbi Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy
    Albert A Hagege
    Assistance Publique Hopitaux de Paris, Department of Cardiology, Hôpital Européen Georges Pompidou and INSERM EMI 16, Necker Paris V University, Paris, France
    Lancet 361:491-2. 2003
    ..6%, respectively, in skeletal muscle). Myoblast grafts can survive and show a switch to slow-twitch fibres, which might allow sustained improvement in cardiac function...
  33. ncbi Mitral valve reconstruction in Barlow disease: long-term echographic results and implications for surgical management
    Jerome Jouan
    Département de Chirurgie Cardio vasculaire, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France
    J Thorac Cardiovasc Surg 143:S17-20. 2012
    ..We aimed to assess whether our most recent results involving several surgeons were comparable with those of a previous experience in which mitral valve repair was performed by a more limited group of surgeons...
  34. ncbi Cardiac stem cells in the real world
    Julia Pouly
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery University Paris 5, Faculty of Medicine, Paris, France
    J Thorac Cardiovasc Surg 135:673-8. 2008
    ..However, data on these endogenous cardiac precursors are primarily derived from animal studies, and their clinical relevance still remains elusive...
  35. ncbi Skeletal myoblast transplantation through a catheter-based coronary sinus approach: an effective means of improving function of infarcted myocardium
    Camille Brasselet
    Assistance Publique Hopitaux de Paris, Department of Cardiology, Hôpital Européen Georges Pompidou et Faculté de Médecine René Descartes, Universite Paris V, Paris, France
    Eur Heart J 26:1551-6. 2005
    ..This study was designed to assess the functional effects of a transvenous coronary sinus technique of skeletal myoblast delivery in infarcted myocardium...
  36. ncbi Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells?
    Etienne Puymirat
    INSERM U633, Laboratory of Biosurgical Research, Hopital Broussais, Paris, France
    Mol Ther 17:176-82. 2009
    ..However, there was only modest evidence for an immunosuppressive effect of coinjected MSCs and their beneficial effects seemed rather mediated by trophic effects on the host tissue...
  37. ncbi A new absorbable collagen membrane to reduce adhesions in cardiac surgery
    Alain Bel
    Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Ecole de Chirurgie, 75908 Paris, France
    Interact Cardiovasc Thorac Surg 10:213-6. 2010
    ..0 [0;3.5] vs. 5.5 [3;7], P=0.01 by Wilcoxon test). The Cova CARD membrane might represent an attractive pericardial substitute for preventing postoperative adhesions in cardiac surgery...
  38. ncbi Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium?
    Onnik Agbulut
    INSERM U633, Paris, France, Assistance Publique Hopitaux de Paris, Ecole de Chirurgie, Paris, France
    Cardiovasc Res 72:175-83. 2006
    ..To assess the functional effects of multipotent adult progenitor cells (MAPCs) transplanted in a rat model of chronic myocardial infarction...
  39. ncbi Cell transplantation for the treatment of heart failure
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Bichat Claude Bernard, Assistance Publique Hopitaux de Paris, Paris, France
    Semin Thorac Cardiovasc Surg 14:157-66. 2002
    ....
  40. ncbi Cellular transplantation: hurdles remaining before widespread clinical use
    Philippe Menasche
    Department of Cardiovascular Surgery and INSERM U 572, Hopital Europeen Georges Pompidou, Paris, France
    Curr Opin Cardiol 19:154-61. 2004
    ..It is thus appropriate to review the most important of these studies in light of the major issues that still impede widespread clinical use of cell therapy...
  41. ncbi Does the human skeletal muscle harbor the murine equivalents of cardiac precursor cells?
    Susanne Proksch
    INSERM U 633, Laboratory of Biosurgical Research, Hopital Broussais, Paris, France
    Mol Ther 17:733-41. 2009
    ..In conclusion, the human skeletal muscle does not harbor cardiac-specified cells but contains a CD34+ fraction endowed with an angiogenic potential providing superior functional and structural benefits...
  42. ncbi A polydioxanone electrospun valved patch to replace the right ventricular outflow tract in a growing lamb model
    David Kalfa
    INSERM U633, Laboratoire de Recherches Biochirurgicales, Paris, France
    Biomaterials 31:4056-63. 2010
    ..A polydioxanone electrospun tissue-engineered valved transannular patch seems to be a promising device in restoring a living RVOT and could ultimately lead to applications in the treatment of congenital RVOT diseases...
  43. ncbi Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass
    Jerome Jouan
    Département de Chirurgie Cardio vasculaire, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    J Thorac Cardiovasc Surg 144:467-73, 473.e1-2. 2012
    ....
  44. ncbi Myoblast-based cell transplantation
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, Paris, France
    Heart Fail Rev 8:221-7. 2003
    ....
  45. ncbi The potential of embryonic stem cells to treat heart disease
    Philippe Menasche
    Hôpital Européen Georges Pompidou and Paris Descartes University, Department of Cardiovascular Surgery and INSERM U633, 20 rue Leblanc, Paris 75015, France
    Curr Opin Mol Ther 7:293-9. 2005
    ....
  46. ncbi Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy
    Onnik Agbulut
    INSERM U572, Hopital Lariboisiere, 41, Bd de la Chapelle, 75475 Cedex 10, Paris, France
    Cardiovasc Res 58:451-9. 2003
    ..To extend the potential of cell transplantation, we assessed this treatment in a mouse model of acute nonischemic doxorubicin-induced cardiomyopathy...
  47. ncbi Routine delivery of myoblasts during coronary artery bypass surgery: why not?
    Philippe Menasche
    University Paris Descartes, Faculte de Medecine, France
    Nat Clin Pract Cardiovasc Med 3:S90-3. 2006
    ....
  48. ncbi Myoblast transfer in heart failure
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, Paris 75018, France
    Surg Clin North Am 84:125-39. 2004
    ....
  49. ncbi Skeletal myoblast transplantation for cardiac repair
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, Paris, France
    Expert Rev Cardiovasc Ther 2:21-8. 2004
    ..Altogether, these efforts should allow the assessment of whether and to what extent cell transplantation may ameliorate function of the failing heart...
  50. ncbi Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell
    Yves Lepelletier
    CNRS UMR 8147, Universite Paris Descartes, Hopital Necker, Paris, France
    Stem Cells Dev 19:1075-9. 2010
    ..Taken together, these results demonstrate the critical role of Galectin-1 and Sema-3A in MSCs functions and may open new perspectives in the understanding and treatment of various immune and neoplastic disorders...
  51. ncbi Skeletal muscle satellite cell transplantation
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, 20, rue Leblanc, 75015, Paris, France
    Cardiovasc Res 58:351-7. 2003
    ....
  52. ncbi Skeletal myoblast for cell therapy
    Philippe Menasche
    Department of Cardiovascular Surgery and INSERM U 633, Hopital Europeen Georges Pompidou, Paris, France
    Coron Artery Dis 16:105-10. 2005
    ....
  53. ncbi [Cellular therapy in cardiology]
    Philippe Menasche
    Departement de Chirurgie Cardiovasculaire, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris, Universite Paris 5, INSERM U633, 20, rue Leblanc, 75908 Paris Cedex 15, France
    C R Biol 330:550-6. 2007
    ..In this setting, the greatest promises are currently held by embryonic stem cells...
  54. ncbi [Perspectives in cardiac cell therapy]
    Philippe Menasche
    Hopitaux de Paris, Hopital Europeen Georges Pompidou, Département de Chirurgie Cardio vasculaire, Universite Paris Descartes, Faculté de Médecine INSERM U 633, AP HP, Paris 75, France
    Presse Med 36:1S55-8. 2007
    ..Three challenges for on optimal therapeutic benefit: prevent cells migration, increase their survival and improve their integration within the recipient myocardium. Many perspectives exist in the field of regeneration of cardiac tissue...
  55. ncbi [Perspectives in cardiac cell therapy]
    Philippe Menasche
    AP HP, Departement de Chirurgie Cardiovasculaire, Hopital Europeen Georges Pompidou, Paris, France
    Presse Med 36:1007-11. 2007
    ..Three challenges remain to obtain optimal therapeutic benefits: prevent the migration of these cells, increase their survival, and improve their integration into the recipient myocardium...
  56. ncbi [Cell therapy: results in Cardiology]
    Philippe Menasche
    Chirurgie cardiovasculaire, Hopital Europeen Georges Pompidou, 20, rue Leblanc 75908 Paris, Universite Paris Descartes, INSERM U633, Paris
    Bull Acad Natl Med 193:559-68; discussion 568-9. 2009
    ..Although several hurdles stand in the way of routine clinical applications, there are serious reasons for hoping that these cells will eventually provide an effective means of repairing diseased myocardial tissue...
  57. ncbi Can magnetic targeting of magnetically labeled circulating cells optimize intramyocardial cell retention?
    Aurélie Chaudeurge
    INSERM U633, Laboratory of Surgical Research, Paris, France
    Cell Transplant 21:679-91. 2012
    ..Magnetic targeting has the potential to enhance myocardial retention of intravascularly delivered endothelial progenitor cells...
  58. ncbi Is there a place for preconditioning during cardiac operations in humans?
    Bruno Pouzet
    Department of Cardiovascular Surgery, Groupe Hĵspitalier Bichat Claude Bernard, Paris, France
    Ann Thorac Surg 73:843-8. 2002
    ..We assessed whether such an activation occurred during cardiac operations and could thus represent a target for cardioprotective strategies...
  59. ncbi Stem cells for clinical use in cardiovascular medicine: current limitations and future perspectives
    Philippe Menasche
    Hopital Europeen Georges Pompidou, Department of Cardiovascular Surgery, Paris, France
    Thromb Haemost 94:697-701. 2005
    ....
  60. ncbi Cell transplantation in myocardium
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, Paris, France
    Ann Thorac Surg 75:S20-8. 2003
    ..In parallel to the experimental studies designed to address these issues clinical trials are under way and should hopefully allow assessing to what extent cell transplantation may improve the outcome of patients with heart failure...
  61. ncbi Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin
    Onnik Agbulut
    EA300, Department of Biochemistry, University Paris Diderot, Paris, France
    J Biol Chem 282:10465-71. 2007
    ..This potential adverse effect of eGFP should be kept in mind when using this marker to track cells following transplantation...
  62. ncbi [Role of stem cells in cardiac repair]
    Philippe Menasche
    , Paris, France
    Bull Acad Natl Med 189:615-22; discussion 622-4. 2005
    ..Their subsequent electromechanical integration into the recipient myocardium can contribute to the repair of the damaged heart...
  63. ncbi Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms
    Olivier Mir
    Department of Oncology, Assistance Publique Hopitaux de Paris, Hopital Cochin, University Paris 5, Faculty of Medicine, Paris, France
    Gynecol Oncol 106:622-5. 2007
    ..Non-bacterial thrombotic endocarditis is a severe complication of cancer, rarely reported in gynecologic tumors. However, it can be inaugural and lead to complex diagnostic pathways...
  64. ncbi Cell therapy of heart failure
    Philippe Menasche
    Department of Cardiovascular Surgery, Hopital Bichat Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France
    C R Biol 325:731-8. 2002
    ....
  65. ncbi Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium
    Patrick Farahmand
    MaRS Centre, Toronto Medical Discovery Tower, Room 3 702, 101 College Street, Toronto, Ontario, Canada
    Circulation 118:S130-7. 2008
    ..We evaluated the roles of these factors in the preservation of matrix architecture (in the infarct and remote regions) by varying the timing (postmyocardial infarction) and delivery site of the implanted cells...
  66. ncbi Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host
    Bertrand Leobon
    Laboratory of Neurophysiology, , EPI 0002, Centre National de la Recherche Scientifique FRE2500, , 75231 Paris, France
    Proc Natl Acad Sci U S A 100:7808-11. 2003
    ..We conclude that mechanisms other than electromechanical coupling between grafted and host cells are involved in the improvement of cardiac function...
  67. ncbi Construction of skeletal myoblast-based polyurethane scaffolds for myocardial repair
    Matthias Siepe
    Clinic for Cardiovascular Surgery, University Hospital Bern, Switzerland
    Artif Organs 31:425-33. 2007
    ..This myoblast seeding technique on PU allows transfer of a large number of living myoblasts to a damaged myocardium...
  68. ncbi Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    JAMA 299:1777-87. 2008
    ..Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery...